STEIN:一种用于无缝I/II期临床试验的简易毒性-疗效区间设计
针对肿瘤早期药物研发中的无缝I/II期剂量探索试验,现有方法多依赖难以验证的复杂模型,实践实施困难。作者将贝叶斯最优区间设计从最大耐受剂量拓展至最优生物剂量,分别通过最小化错误分类概率推导毒性与疗效的优化区间。所提区间设计无需模型,适用于多种剂量-反应关系;模拟研究显示其在小样本和大样本下均具有良好且稳健的操作特性,且比现有I/II期剂量探索设计更易实施。
要点
- 将贝叶斯最优区间设计从最大耐受剂量拓展至I/II期最优生物剂量探索。
- 毒性与疗效优化区间分别通过最小化错误分类概率推导。
- 所提设计无需模型,模拟显示其操作特性良好且稳健,比现有设计更易实施。
核心结论
- 所提区间设计无需模型,适用于多种剂量-反应关系,且比现有I/II期剂量探索设计更易实施并具有良好且稳健的操作特性。
研究设计与样本
- 方法学文章,将贝叶斯最优区间设计从最大耐受剂量探索拓展至无缝I/II期试验的最优生物剂量探索。
- 通过广泛模拟研究在不同情景下评估所提方法的小样本和大样本性能。
主要发现
- 毒性与疗效的优化区间分别通过最小化错误分类概率推导。
- 若当前剂量下观察到的毒性与疗效概率对位于有希望区域内,则保留当前剂量。
- 若观察概率位于有希望区域外,则提出分配规则:在仍控制毒性水平的前提下,最大化下一剂量缓解率落在预设疗效概率区间内的后验概率。
- 模拟研究表明所提方法在不同情景下具有良好且稳健的操作特性。
关键数值与推荐
- 毒性与疗效优化区间分别通过最小化错误分类概率推导。
- 若当前剂量下观察到的毒性与疗效概率对位于有希望区域内,则保留当前剂量;若位于区域外,则在控制毒性水平的前提下最大化下一剂量缓解率落在预设疗效概率区间内的后验概率以分配剂量。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Seamless phase I/II dose-finding trials are attracting increasing attention nowadays in early-phase drug development for oncology. Most existing phase I/II dose-finding methods use sophisticated yet untestable models to quantify dose-toxicity and dose-efficacy relationships, which always renders them difficult to implement in practice. To simplify the practical implementation, we extend the Bayesian optimal interval design from maximum tolerated dose finding to optimal biological dose finding in phase I/II trials. In particular, optimized intervals for toxicity and efficacy are respectively derived by minimizing probabilities of incorrect classifications. If the pair of observed toxicity and efficacy probabilities at the current dose is located inside the promising region, we retain the current dose; if the observed probabilities are outside of the promising region, we propose an allocation rule by maximizing the posterior probability that the response rate of the next dose falls inside a prespecified efficacy probability interval while still controlling the level of toxicity. The proposed interval design is model-free, thus is suitable for various dose-response relationships. We conduct extensive simulation studies to demonstrate the small- and large-sample performance of the proposed method under various scenarios. Compared to existing phase I/II dose-finding designs, not only is our interval design easy to implement in practice, but it also possesses desirable and robust operating characteristics.
引用
- Lin R, Yin G. STEIN: A simple toxicity and efficacy interval design for seamless phase I/II clinical trials. Stat Med. 2017. PMID: 28786138. doi:10.1002/sim.7428
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。